drugset
drugset / Trial / NCT03444766

Study of Nivolumab for Advanced Cancers in India

NCT03444766 ↗

Phase 4 Completed 100 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.

Timeline

Start
2018-03-06
Primary completion
2019-07-17
Completion
2019-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody — —

Indications

kidney cancer non-small cell lung carcinoma